A Phase 2a, multi-center, single-blind, within-subject, placebo-controlled study to assess the pharmacodynamics of ACT-709478 in subjects with photosensitive epilepsy

Trial Profile

A Phase 2a, multi-center, single-blind, within-subject, placebo-controlled study to assess the pharmacodynamics of ACT-709478 in subjects with photosensitive epilepsy

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs ACT 709478 (Primary)
  • Indications Reflex epilepsy
  • Focus Pharmacodynamics
  • Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
  • Most Recent Events

    • 22 Sep 2017 Planned End Date changed from 1 Oct 2018 to 30 Sep 2018.
    • 22 Sep 2017 Planned primary completion date changed from 1 Oct 2018 to 30 Sep 2018.
    • 22 Sep 2017 Planned initiation date changed from 11 Sep 2017 to 9 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top